WELCOME TO Million Health Pharmaceuticals

The most important prescribing information of Bevarest is; Metastatic colorectal cancer Non-squamous non-small cell lung cancer Recurrent Glioblastoma Advanced renal cell cancer Advanced cervical cancer Epithelial ovarian, fallopian tube or primary peritoneal cancer

Bevacizumab link to the VEGF and inhibits the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The combination of VEGF with its receptors causesendothelial cell replication and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.

ADME Properties


The pharmacokinetic of Bevarest is to be linear; the concluded time to reach more than 90% of steady state concentration is 84 days. The median trough concentration of Bevacizumab is 80.3mcg/ml on day 84.


Volume of distribution of Bevacizumab is 2.9L


The drug has been accomplished with opsonization for excretion. This may occur through reticuloendothelial system at time of binding to endothelial cells.


The terminal half-life period of Bevacizumab is nearly 20 days.


Brand : Bevarest
Ingredients : Bevacizumab
Strength : 100mg/4ml
Manufactured : Emcure
Package : one vial in a carton

Dosage regimens and administration of Bevarest

The most important administration factors are, Bevarest should not be used until at least 28 days following surgery and lesion is completely healed.

Metastatic colon rectal cancer

The prescribed dose when Bevarest is administered in co administration with intravenous 5-fluorouracil-based chemotherapy is: Patient Administrate 5 mg/kg every 2 weeks intravenously in combination with bolus-IFL. Patient Administrate 10 mg/kg every 2 weeks intravenously in combination with FOLFOX4. Patient Administrate 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Bevarest -containing regimen.

Non-squamous non-small cell lung cancer

The usual dose of Bevarest is 15mg/kg should be administered via IV for every 2 weeks by interaction with carboplatin & paclitaxel.

Recurrent Glioblastoma

The usual dose of Bevarest is 10mg/kg should be administered IV for every 2 weeks

Advanced renal cell cancer

The usual suggested dose of Bevarest is 10mg/kg should be given intravenously for every 2 weeks by co administration with interferon alfa.

Advanced cervical cancer

The prescribed dose of Bevarest in this condition is 15mg/kg of drug should be given intravenously for every 3 weeks by interaction with paclitaxel & cisplatin or by combining with paclitaxel & topotecan.

Epithelial ovarian, fallopian tube, or peritoneal cancer

Therapy of stage III or IV: The usual dose of Bevarest is 15mg/kg IV for every 3 weeks by concomitant with carboplatin & paclitaxel for period of 6 cycles, continued by Bevarest 15mg/kg for every 3 weeks as a single regimen, for total duration of treatment is 22 cycles.


Bevarest should be givenvia intravenous infusion over the period of 90 minutes as first infusion and consecutive infusions may follow over 60 minutes. 100mg of Bevarest containing 4ml solution which is diluted in 100ml of 0.9% sodium chloride solution. Bevarest should not be diluted in dextrose solution. Bevarest should be administered as intravenous site. It should be administered with or without food.


There is no chance of getting over dosage in Bevarest getting patients, because Bevarest is a cytotoxic drug which is administered only under the supervision of medical oncologist. Bevarest should be used cautiously.

The most common adverse effects in Bevarest treatment

GI perforations & fistulae, Surgery and wound healing complications, Hemorrhage, Arterial thromboembolic events, Venous thromboembolic events, Hypertension, Posterior reversible encephalopathy syndrome, Renal damage & Proteinuria, Infusion reactions, Ovarian failure, Congestive heart failure


Some warning signs should be taken into consideration; Gastrointestinal perforation, surgery & wound lesions complexity or hemorrhages are the major adverse effect occurs during the treatment with Bevarest injection.


Increased blood pressure in patients who are receiving Bevarest therapy, should be monitor frequently with blood pressure and provided with alternative medication for correct the pressure. In hypertension crisis or encephalopathy should be discontinue the treatment.

Arterial thromboembolic events

Discontinue the therapy with Bevarest in patients who are suffered with severe ATE. Venous thromboembolic events: Incidence of toxicity should be detected; in case of severe condition therapy should be stopped.

In GI perforation

Treatment should be discontinued and providing supportive measures In wound or surgery complications: Bevarest treatment should be interrupt during the surgery until the wound should be completely healed. Nearly 28 days after & before the surgery, therapy should be withheld.


Severe hemorrhages like GI bleeding, hemoptysis, Hematemesis, CNS hemorrhage, Epistaxis & vaginal bleeding are occurring during the Bevarest treatment. Discontinue the treatment.

Posterior reversible encephalopathy syndrome

Symptoms should be cleared with providing supportive measures after discontinuing the Bevarest therapy and PRES should be monitored by undergoing MRI. In severe condition, patients should be discontinuing with Bevarest treatment.

In renal injury & Proteinuria

Toxicity grade should be resolved by monitoring the renal function and Proteinuria. Infusion reactions: In severe infusion reactions, patients should not take Bevarest treatment.

Embryo fetal damage

Bevarest is contraindicated to pregnancy condition, produce fetal harm.

Ovarian failure

Bevarest receiving patients may have a chance of getting ovarian failure.

Congestive heart failure

In anthracycline based chemotherapy, Bevarest treatment should not be used. Bevarest treatment should be discontinuing while CHF occurs.

Drug- drug interaction

Bevarest interaction with paclitaxel & carboplatin causes decrease exposure of paclitaxel after completion of 4 cycles of therapy. When patients getting paclitaxel & carboplatin as alone, causes elevation of paclitaxel exposure at day 63.

Quick Contact

Prescription upload


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.